The project is agreed as a joint collaboration among IBAR, ATOMKI and UD, the latter being a cost free participant. There are two main directions envisaged by the proposed project: - receptors mapping and therapy, using an affibody against HER2 receptors, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establishing labelling procedures; c) ex vivo and/or in vivo testing of optimal compounds.
Under construction
......
10 may 2023: Seminar IBAR
1. Lecture title: "Labelling anti-HER2-affibodies with 52Mn via pyclen based bifunctional ligands: from ligand to in vivo PET/MR experiments"
-Balazs Varadi, PhD(c), Department of Physical Chemistry, Faculty of Science and Technology, University of Debrecen, Hungary, Institute for Nuclear Research, Debrecen, Hungary.
2. Lecture title: "Designing macrocyclic ligands for biomedical application"
-Professor Gyula Tircso, PhD, Department of Physical Chemistry, Faculty of Science and Technology, University of Debrecen, Hungary.
2 september 2024: "Ion Heliade Radulescu Auditorium" Romanian Academy; Frontiers in Biochemistry: Romania-China Collaborative Perspectives
Lecture title: "Rationally-Designed Targeting Agents in Cancer and Neurodegenerative Disorders" - PhD student, Andrei - Mihai Vasilescu
Publication:
1. "Mn(II)-based diagnostic agents: from basic research to targeted diagnostic procedures"; Balázs Váradi, Gergő Zoltán Sajtos, Károly Brezovcsik, Zoltan Szűcs, Stefan Szedlacsek, Gábor Nagy, Gyula Tircso; Scientia et Securitas 5(2): 253-266, 2024 Nov25 doi: https://doi.org/10.1556/112.2024.00208
2. Editorial: „Molecular targets in oncological and hematological disease management: innovations in precision medicine"; Adrian Bogdan Tigu, Gregory Wiedman, Stefan Eugen Szedlacsek; Frontiers in Pharmacology; 2024 Sep 20 DOI: 10.3389/fphar.2024.1494396